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The protein tyrosine phosphatase PTP1B is a major regulator of glucose homeostasis and
energy metabolism, and a validated target for therapeutic intervention in diabetes and
obesity. Nevertheless, it is a challenging target for inhibitor development. Previously, we
generated a recombinant antibody (scFv45) that recognizes selectively the oxidized, inactive
conformation of PTP1B. Here, we provide a molecular basis for its interaction with reversibly
oxidized PTP1B. Furthermore, we have identiﬁed a small molecule inhibitor that mimics the
effects of scFv45. Our data provide proof-of-concept that stabilization of PTP1B in an inactive,
oxidized conformation by small molecules can promote insulin and leptin signaling. This work
illustrates a novel paradigm for inhibiting the signaling function of PTP1B that may be
exploited for therapeutic intervention in diabetes and obesity.
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Obesity and type 2 diabetes, together with their cardio-vascular complications, pose a serious threat to publichealth in the 21st century. According to the American
Diabetes Association, almost 10% of the US population has dia-
betes, with 86 million Americans over the age of 20 in a pre-
diabetic state. Furthermore, the WHO highlights that 422 million
people worldwide were afﬂicted with diabetes in 2014, compared
to 108 million in 1980. These numbers are expected to grow in
the next few decades, with a prevalence of 600 million projected
by 20351,2. Type 2 diabetes, which is caused by insulin resistance
resulting in loss of normal glucose homeostasis, accounts for
>90% of all diabetes. This disease used to be referred to as
“adult- or maturity-onset” diabetes, but is now also becoming
more prevalent throughout the population, including in children.
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Fig. 1 Molecular characterization of PTP1B-scFv45 interaction. a Overlay of PTP1B (gray) and TCPTP (pale blue) crystal structures, highlighting residues
that are changed in generating mutant forms (-mut1 and -mut2) of the enzymes. b Increasing concentrations of recombinant HA-tagged scFv45 were
incubated with oxidized wild-type (-wt) or mutant (-mut) forms of PTP1B (top panel) and oxidized wild-type or mutant forms of TCPTP (bottom panel).
The protein complexes were precipitated with anti-HA-agarose beads and equivalent amounts of input, supernatant, and eluate were subjected to
immunoblot analysis. Data are representative of at least three independent experiments (n= 3). c Michaelis–Menten plots for wild-type (circle), -mut1
(square), or -mut2 (triangle) forms of PTP1B (left) and TCPTP (right) are shown. Radiolabeled 32PY-RCML was used as substrate to measure phosphatase
activity. Individual data points represent the mean obtained from three separate experiments (n= 3). d Wild-type and mutant forms of PTP1B were
incubated with increasing concentrations of H2O2 and phosphatase activity was measured using DiFMUP in the absence (black bar) and presence (gray
bar) of the reducing agent TCEP (5 mM). e Oxidized PTP1B-wt (circle), PTP1B-mut1 (square), or PTP1B-mut2 (triangle) were incubated with increasing
concentration of scFv45 (0–1000 nM) and phosphatase activity was measured using DiFMUP as substrate in the presence of the reducing agent TCEP (5
mM). Data represent mean± s.e.m. from three separate experiments (n= 3; d, e)
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This illustrates that therapeutic options for treating diabetes and
obesity are inadequate, and effective approaches to counter the
disease are urgently needed.
The ability to modulate signal transduction pathways selec-
tively holds enormous therapeutic potential. The protein tyrosine
phosphatase PTP1B, which is a negative regulator of insulin and
leptin signaling, is a highly validated target for therapeutic
intervention in diabetes and obesity3,4. The PTPN1 gene, which
encodes PTP1B, is located in 20q13, a genomic region that is
linked to insulin resistance and diabetes in human populations
from different geographical origins. More than 20 single
nucleotide polymorphisms (SNPs) that are associated with
increased risk of type 2 diabetes have been identiﬁed within the
PTPN1 gene5. Whole-body deletion of PTP1B in mice resulted in
increased insulin sensitivity and improved glucose tolerance6,7.
These animals were found to be lean, hypersensitive to leptin and
resistant to diet-induced obesity8,9. In addition to improved
glucose homeostasis, hepatic PTP1B deletion was found to con-
tribute to positive lipid metabolic changes in both liver and cir-
culation10. The serum cholesterol levels in these animals were
found to be lower than in control littermates, even when sub-
jected to a high fat diet for a prolonged period of time. Con-
versely, insulin resistance can result in hepatic fat accumulation,
which is a signiﬁcant contributor to non-alchoholic steatohepa-
titis (NASH)10,11. In addition, liver biopsies from patients with
NASH also revealed an increase in PTP1B levels12. In light of
such data, considerable interest has grown in the potential of
PTP1B as a therapeutic target for treating diabetes and obesity.
Consequently, there have been substantial programs in industry
focused on developing small molecule inhibitors of this phos-
phatase. All of these programs followed standard procedures of
looking for active site-directed inhibitors; however, these efforts
have been frustrated by technical challenges arising from the
chemical properties of the PTP active site. The end result has
been that although it was possible to generate potent, speciﬁc, and
reversible inhibitors of PTP1B, such molecules were highly
charged and thus of low oral bioavailability and limited drug
development potential13,14. Hence, alternative strategies are nee-
ded to develop drugs against this highly validated therapeutic
target.
In one such approach, we wanted to harness a physiological
regulatory mechanism in which tyrosine phosphorylation-
dependent signaling, such as in response to insulin, triggers the
localized production of reactive oxygen species, in particular H2O2,
leading to inactivation of PTP1B through reversible oxidation of the
phosphatase. This represents a mechanism for ﬁne-tuning the sig-
naling response15,16. Previously, we used phage display technology
to generate a library of conformation-sensor antibodies that
recognize epitopes unique to the reversibly oxidized form of PTP1B
(PTP1B-OX), which are not displayed in the active, reduced form of
the enzyme17. We characterized these conformation-sensor anti-
bodies, such as scFv45, which stabilized the reversibly oxidized,
inactive form of PTP1B. Following expression in cells, scFv45
trapped the oxidized form of PTP1B, preventing its reduction and
reactivation, which resulted in enhanced and sustained insulin-
induced signal transduction. These conformation-sensor antibodies
displayed remarkable speciﬁcity. For example, scFv45 did not bind
to the reduced form of PTP1B, nor did it recognize TCPTP (either
in the reduced or oxidized form), which displays ~75% sequence
identity to PTP1B in its catalytic domain. Although this profound
speciﬁcity would be an asset to a drug candidate, such antibodies
are unlikely to be developed therapeutically. Nevertheless, a small
molecule that mimics the effects of these antibodies could have
therapeutic potential.
In this study, we have identiﬁed the binding site for scFv45 on
PTP1B-OX and present a molecular basis for the speciﬁcity of
this interaction. We observed that, in addition to insulin signal-
ing, scFv45 enhanced the activation of signaling in response to
leptin. Furthermore, we present the identiﬁcation and char-
acterization of candidate small molecule inhibitors that mimic the
effects of the scFv45 antibody on signal transduction. The char-
acterization of one such small molecule, chelerythrine, illustrates
the exciting possibility that stabilization of the oxidized, inactive
form of PTP1B with appropriate therapeutic small molecules may
be exploited to improve insulin and leptin signaling. Overall, this
study provides proof-of-principle for a novel approach to PTP-
based drug development that circumvents the challenges posed by
the chemistry of the PTP active site.
Results
Molecular basis for the interaction between scFv45 and
PTP1B-OX. Reversible oxidation of PTP1B is accompanied by
profound conformational changes in the protein, particularly in
the active site18,19. Although PTP1B and TCPTP are closely
related in sequence, there are residues that are unique to each
enzyme, including on the surface of the proteins close to the
active site (Fig. 1a). We used mutagenesis and subsequent binding
assays with scFv45 to identify residues in PTP1B that are
important for the interaction between the two proteins. Several
mutant forms of PTP1B were generated following comparison of
its sequence and structure with that of TCPTP, and substitution
of those residues from TCPTP into the corresponding PTP1B
sequence. Conversely, chimeric TCPTP mutants containing
residues substituted from PTP1B were also generated. We focused
on two mutant constructs, a control designated PTP1B-mut1, and
PTP1B-mut2 (Fig. 1a), and identiﬁed three important residues in
the binding interface between PTP1B and scFv45. Using a co-
immunoprecipitation assay, we observed that, compared to the
wild-type enzyme, PTP1B-wt, the binding interaction between
scFv45 and reversibly oxidized PTP1B-mut2 (L37F/K39E/K41R)
was abrogated (Fig. 1b). Conversely, introduction of these three
residues (Leu37, Lys39, and Lys41) into TCPTP was sufﬁcient to
promote binding between scFv45 and reversibly oxidized TCPTP-
mut2 (F39L/E41K/R43K) (Fig. 1b). Similar substitution of S28H/
F30Y/C32H to generate PTP1B-mut1 did not interfere with
binding of scFv45, nor did the converse mutations in TCPTP-
mut1 gain binding (Fig. 1b). Using the artiﬁcial substrate 32PTyr-
RCML to assay phosphatase activity, we observed that the speciﬁc
activity of PTP1B-mut1 and PTP1B-mut2 was comparable to that
of PTP1B-wt (Fig. 1c). Furthermore, PTP1B-mut1 and PTP1B-
mut2 were reversibly oxidized by H2O2 and reactivated by the
reducing agent TCEP in a similar manner to wild-type PTP1B
(Fig. 1d). Upon incubation of the reversibly oxidized forms of
PTP1B-wt and PTP1B-mut1 with scFv45, the reduction and
reactivation of the enzyme was impaired in a dose-dependent
manner (Fig. 1e); in contrast, scFv45 did not attenuate the
reduction and reactivation of reversibly oxidized PTP1B-mut2.
Taken together, these data demonstrate that Leu37, Lys39, and
Lys41 in the loop comprising residues 36–41 in PTP1B-OX are
critical for scFv45 binding independently of an effect on phos-
phatase activity or reversible oxidation.
Following mutation of the catalytic Cys215 and adjacent
Ser216 to alanine (PTP1B-CASA), PTP1B adopts a conformation
that is identical to that of the reversibly oxidized sulfenyl-amide
form (PTP1B-OX)17. Therefore, this mutant allows us to
investigate scFv45 binding on a homogenous background,
ensuring that any sample heterogeneity caused by incomplete
oxidation during sulfenyl-amide formation is eliminated. In a
complementary approach to the analysis by mutagenesis
described above, we examined the interaction of scFv45 with
PTP1B-CASA using analytical size-exclusion chromatography.
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We observed that unlike PTP1B-CASA, PTP1B-CASA-mut2 was
unable to associate with scFv45, whether in excess or at limiting
molar ratios (Fig. 2a; Supplementary Fig. 1a, b). Moreover, when
similar experiments were performed with TCPTP-CASA and
TCPTP-CASA-mut2, we observed a gain-of-association in
TCPTP-CASA-mut2, compared to TCPTP-CASA, suggesting
that TCPTP-CASA-mut2 adopts a similar architecture to that of
PTP1B-OX and PTP1B-CASA (Supplementary Fig. 2). These
data are in agreement with the binding studies using oxidized and
mutant forms of PTP1B and TCPTP (Fig. 1), and support the
utility of CASA mutants, and further mutants thereof, for detailed
analysis of scFv45 association. Similarities in the reversible
oxidation and catalytic properties of PTP1B and PTP1B-mut2
(Fig. 1b–e), together with the uniform chromatographic proﬁles
of PTP1B-CASA and PTP1B-CASA-mut2 (Fig. 2a), suggest that
the inability for PTP1B-CASA-mut2 to associate with scFv45 was
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likely due to a lack of key binding determinants rather than a
consequence of gross structural perturbations.
We used a combination of unbiased (by proteolytically
targeting Asp residues) and biased (by proteolytically targeting
Lys residues) mass spectrometry-based structural proteomics to
characterize this interaction further and deﬁne residue bound-
aries for segments of PTP1B involved in association with scFv45.
Upon complex formation between PTP1B-CASA and scFv45, we
observed that proteolytic cleavage at Asp28 by endoproteinase
AspN was nearly undetectable, whereas in the absence of scFv45
or in mixtures of PTP1B-CASA-mut2 with scFv45, cleavage at
this site was readily observed (m/z 827.4; Fig. 2b; Supplementary
Fig. 3a, b). Accessibility of proximal, amino-terminal cleavage
sites at Asp22 and Asp53 (m/z 2521.1 and 1262.7), as well as
those in the carboxyl-terminus (m/z 1171.5 and 2296.3), were
independent of PTP1B-CASA association with scFv45 (Fig. 2b;
Supplementary Fig. 3a, b). Also, we observed a marked reduction
in the relative accessibility of amino-terminal proteolytic cleavage
sites towards endoproteinase LysC in complexes of PTP1B-CASA
and scFv45, speciﬁcally at Lys39 and Lys41 (m/z 2403 and 2161,
respectively; Fig. 2c; Supplementary Fig. 4a, b). Cleavage at
amino-terminal sites Lys12 and Lys58 (m/z 1557 and 1773,
respectively), as well as in the carboxyl-terminus (m/z 879 and
3370), was independent of association with scFv45. Overall, these
data suggest regional boundaries of the binding interface from
Ile23 to Phe52 (Fig. 2c, d; Supplementary Figs. 3 and 4).
Complementary analysis by protein electrophoresis supports that
the observed variations among these initial proteolytic events
sampled were the result of scFv45 association with PTP1B-CASA
and not the consequence of exhaustive digestion inducing
protein unfolding or degradation of either PTP1B or scFv45
(Supplementary Fig. 5).
To provide further insights into the molecular details of the
interaction between scFv45 and the reversibly oxidized form of
PTP1B, we determined the crystal structure of scFv45 at 1.6 Å
resolution (Table 1). This single-chain variable fragment (scFv)
antibody contains only the variable light (VL) and variable heavy
(VH) chains of the antigen-binding fragment (Fab) connected by
an 18 amino acid linker20. The structure consists of the VH and
VL chains, with no electron density observed for the linker region,
in accordance with other reported scFv X-ray crystal structures21.
Within scFv45, acidic residues dominate the hypervariable
complementarity-determining region (Fig. 3a). This feature is
shared among all the scFvs that were identiﬁed as being inhibitory
to reduction and reactivation of PTP1B-OX17. It is interesting to
note also that PTP1B-OX presents a high density of basic residues
near the active site, which have an important role in scFv45
binding, with Arg47 fully exposed in comparison to reduced
PTP1B (Figs. 1 and 2).
Attempts to produce crystals of a puriﬁed complex of scFv45
and PTP1B-OX were unsuccessful. Therefore, we performed an in
silico docking approach using Cluspro software with Antibody
Mode option, with svFv45 as a receptor and PTP1B-OX as a
ligand to generate a low-energy structure of the complex. From
the model it was clear that acidic residues dominated the
complementarity-determining region (CDR) of scFv45; Asp89
and Asp93 of scFv45 formed hydrogen-bonding interactions with
basic residues Arg47 and Lys41 of PTP1B-OX, respectively
(Fig. 3b). By mapping the regional boundaries of the binding
interface that were determined by our structural proteomic
approach onto this model, we noted strong corroboration
between the individual datasets (Figs. 2d and 3b). We also
generated electrostatic maps for PTP1B-OX, scFv45 and scFv20
using the Adaptive Poisson–Boltzmann Solver (APBS) tool in
PyMol (Fig. 3c). The acidic residues of scFv45 in the CDR region,
which are critical for interaction with PTP1B-OX, were found to
be lacking in scFv20, suggesting a molecular explanation for the
lack of interaction observed between PTP1B-OX and scFv2017.
Small molecule inhibitors that stabilize PTP1B-OX. We have
demonstrated that we can generate reversibly oxidized pools of
PTP1B in vitro, with reproducible reactivation by reducing agents
such as TCEP (Fig. 1d). Therefore, our approach has been to
adapt this assay, which we used to screen for conformation-
sensor scFvs17, now to screen for small molecules that act through
a similar mechanism. Our primary screening assay tested the
ability of small molecule inhibitors to antagonize the reduction
and reactivation of the oxidized conformation of PTP1B, similar
to that of scFv45 (Fig. 4a). Therefore, in the presence of small
molecules that do not stabilize the oxidized form of PTP1B, we
expect to observe restoration of enzymatic activity, and depho-
sphorylation of the ﬂuorogenic substrate DiFMUP to the level
observed in controls treated with reducing agent alone; in con-
trast, with any small molecules that stabilize the oxidized con-
formation of PTP1B, the restoration of enzymatic activity would
be impaired.
PTP1B was titrated with varying concentrations of H2O2 to
optimize the concentration at which the enzyme would be stably,
reversibly oxidized for a period of 30–60 min. This is critical as
the overall time to complete the assay in an HTS (High-
Throughput Screen) set up could vary between 30 and 60 min and
within that period of time it is essential to maintain standard
conditions in all assays. PTP1B was then reversibly oxidized in
large batches with H2O2. The oxidized enzyme was incubated
without (high signal) and with (low signal) scFv45 for 5 min,
following which the enzyme was reactivated with TCEP. The high
and low signals were used to calculate the Z-prime value of 0.75
for the assay. The ﬂuorescence signal was robust and the
difference between the high and low signal was ~25-fold
(Supplementary Fig. 6).
The assay was validated using the LOPAC library (Library of
Pharmacologically Active Compounds), which contains 1280
compounds (Fig. 4a). Two compounds in the library were found
to stabilize partially the oxidized conformation; addition of the
reducing agent TCEP did not increase the ﬂuorescence intensity
Fig. 2 Oxidation-induced conformation of PTP1B exposes an amino-terminal binding interface targeted by scFv45. a Analytical size-exclusion
chromatography of PTP1B-CASA and PTP1B-CASA-mut2 in the absence or presence of 1.1-fold molar excess of scFv45. b Mass spectra of PTP1B-CASA
and PTP1B-CASA-mut2 in the absence or presence of 1.1-fold molar excess of scFv45, digested with AspN endoprotease (1:500 w/w) for 30min. Peptide
masses deﬁning regional boundaries of PTP1B-CASA proteolytic protection are shown in bold, with those directly protected being highlighted (blue
rectangle). c Mass spectra of PTP1B-CASA in the absence or presence of 1.1-fold molar excess scFv45, digested with LysC endoprotease (1:750 w/w) for
30min, mixed with internal peptide standards (~42.5 fmol). Masses of internal peptide standards are shown in bold, with those peptide masses of PTP1B-
CASA directly protected from proteolysis being enlarged and in bold. Scaled insets are of the highlighted (blue rectangle) spectral regions. All data are
representative of at least two independent experiments (n≥ 2; a–c). d Three-dimensional crystal structure of PTP1B-CASA, highlighting the regional
boundaries corresponding to the segment protected from proteolysis upon association with scFv45 (Ile23—Phe52). Below is the amino acid sequence of
the N-terminal portion of PTP1B in which residues that were (yellow triangles) or were not (grey triangles) protected from proteolysis are highlighted.
Theoretical AspN and LysC cleavage sites (underlined) and mutated residues in PTP1B-CASA-mut2 (bold) are shown
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to the same extent as that of the positive control (without any
inhibitor or scFv45). With both hits, sanguinarine and levamisole,
TCEP was only able to restore enzymatic activity partially
(Fig. 4a). Similar results were obtained with a distinct reducing
agent, dithiothreitol (DTT). By titrating varying concentrations of
sanguinarine and levamisole against PTP1B-OX we were able
calculate an IC50 of 25 μM for sanguinarine (Fig. 4b) and 36 μM
for levamisole (Fig. 4c). These compounds had no effect on the
activity of the reduced form of PTP1B. To highlight further the
signiﬁcance of the hits, and to conﬁrm that their inhibitory effects
were not due to non-speciﬁc denaturation, we demonstrated that
their effects were reversible by initiating enzymatic assays
following increasing incubation times of compound-bound
PTP1B-OX in the presence of reducing agent (Fig. 4d, e).
Of the two hits, sanguinarine was found to be the more potent
at stabilizing PTP1B-OX, therefore, we focused our attention on
this molecule. In searching for analogs with improved inhibitory
potency, we identiﬁed chelerythrine, chelidonine, palmatine, and
protopine, which contained a similar benzophenanthridine
scaffold, but with minor changes to the functional groups
(Figs. 4f, g; Supplementary Fig. 7). Of these compounds,
chelerythrine was shown to be the most potent at stabilizing
PTP1B-OX, with an IC50 of 5 μM (Fig. 4f) and at least 100-fold
preference over reduced PTP1B. The effects of chelerythrine were
reversible (Supplementary Fig. 8) and direct binding of
chelerythrine to PTP1B-CASA was demonstrated by ITC
(Supplementary Fig. 9). The structurally similar molecule,
protopine was ineffective in inhibiting either the reduced form
of PTP1B, or the reduction and reactivation of the oxidized
enzyme (Fig. 4g). These data illustrate that PTP1B-OX can be
selectively targeted by small molecules and suggest the beginnings
of a structure–activity relationship.
Mechanism of PTP1B-OX stabilization by chelerythrine. Three
crystal structures were selected for a molecular modeling
approach to identify and compare potential predicted binding
sites on PTP1B. One (PDB ID: 1OEM) represented PTP1B-OX,
whereas the other two represented the reduced form of PTP1B
with the active site in either the open (PDB ID: 1T4J) or closed
(PDB ID: 1A5Y) conformation17,22,23. The general conformation
of PTP1B-OX resembles that of the open form of PTP1B. A key
difference in the structures is that Tyr46 does not form a
hydrogen bond with Ser216 in PTP1B-OX, but instead is oriented
away from the active site17,18. Each structure was treated with
Schrödinger’s SiteMap module, which identiﬁes potential binding
sites based on the donor, acceptor and hydrophobic character of
regions within the structure, and the extent to which a ligand may
form substantive interactions with these regions. Five top-scoring
sites were found for each conformation, one of which was
unique to PTP1B-OX. This unique site encompassed a loop
composed of residues 36–46, which contains Tyr46 and is the
segment of the protein that we identiﬁed as important for the
selective recognition of PTP1B-OX by the antibody scFv45
(Figs. 1–3).
The two compounds that were conﬁrmed hits from the
LOPAC 1280 library screen, sanguinarine and levamisole, were
docked using Schrödinger’s Glide module with the unique
potential binding site of PTP1B-OX that was predicted by
SiteMap. Interestingly, sanguinarine, but not levamisole, appeared
to form a π-stacking interaction with Tyr46, perhaps accounting
for its stronger ability to prevent reduction of PTP1B-OX to the
active form of the enzyme (Supplementary Fig. 10a, b). The
sanguinarine analog chelerythrine displayed improved potency,
with a ﬁvefold lower IC50, although the only structural difference
from sanguinarine is the rotatable methoxy groups (Fig. 4f).
When chelerythrine was docked into the unique site identiﬁed by
SiteMap, as described above, it also formed a π-stacking
interaction with Tyr46 (Fig. 5a). Residues Lys36, Lys41, and
Asn44, which we had identiﬁed previously as potentially
contributing to the binding of sanguinarine, also appeared to
contact chelerythrine (Fig. 5a; Supplementary Fig. 10a). A
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Fig. 3 Crystal structure of scFv45 and molecular explanation for scFv45 speciﬁcity for PTP1B-OX. a Crystal structure of scFv45 highlighting acidic residues
Asp89, Glu88, and Asp93 in the complementarity-determining region (CDR). For representative numbering of scFv45 residues, the ﬁrst amino acid
denotes the residue directly following the OmpA cleavage site. bMolecular modeling of the PTP1B-OX:scFv45 complex, with PTP1B-OX shown in gray, and
the regional boundaries of the scFv45-binding interface determined by our structural proteomic approach shown in yellow. The inset shows H-bonding
between residues of PTP1B-OX (K41, Y46, and R47) and the acidic residues in the CDR of scFv45. c Surface electrostatic potential of PTP1B-OX (left),
scFv45 (middle), and scFv20 (right)
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restrained minimization was conducted on the docked model of
chelerythrine with PTP1B-OX using Schrödinger’s Macromodel.
The results of the ﬁnal treatment indicated an additional
hydrogen bond between Arg45 and the methoxy groups of
chelerythrine (Fig. 5a). We performed a mutational analysis to
test this model and to understand further the interaction between
the compound and the protein. We found that when both
residues Lys36 and Lys41 were mutated to alanine, there was a
0 500 1000 1500
0
5000
10,000
Compounds
F
lu
or
es
ce
nc
e 
(a
.u
.)
PTP1B-Red
(active)
PTP1B-OX
(inactive) 
H2O2
+ Compound 
+ TCEP
a
f g
b c
d e
Levamisole
0.1 1 10 100
Sanguinarine
Sanguinarine (µM)
PTP1B-Red
PTP1B-OX
0.1 1 10 100
Levamisole (µM)
PTP1B-Red
PTP1B-OX
Time (min)
0 30 60 90 120 0 30 60 90 120
Time (min)
0.1 1 10 100 1000 0.1 1 10 100 1000
0
25
50
75
100
Chelerythrine (µM)
P
ho
sp
ha
ta
se
ac
tiv
ity
 (
%
)
0
25
50
75
100
P
ho
sp
ha
ta
se
ac
tiv
ity
 (
%
)
0
25
50
75
100
P
ho
sp
ha
ta
se
ac
tiv
ity
 (
%
)
0
25
50
75
100
P
ho
sp
ha
ta
se
ac
tiv
ity
 (
%
)
0
25
50
75
100
P
ho
sp
ha
ta
se
ac
tiv
ity
 (
%
)
0
25
50
75
100
P
ho
sp
ha
ta
se
ac
tiv
ity
 (
%
)
PTP1B-OX
PTP1B-Red
Protopine (µM)
PTP1B-Red
PTP1B-OX
N
N
S
N
+ O
O
O
O
N
+ O
O
O
O
O
O N
O
O
O
Fig. 4 Identiﬁcation and characterization of small molecules that mimic the effect of scFv45. a Reversibly oxidized PTP1B (PTP1B-OX) was generated by
incubation with H2O2 in vitro, desalted, then assayed (20 nM) in the presence and absence of individual members of the LOPAC library. In the right panel,
each dot represents an activity measurement. With two compounds, the reduction and reactivation of PTP1B-OX by TCEP was attenuated. The structures
of these two compounds, levamisole and sanguinarine, are provided. Data are representative of at least two independent experiments (n= 2). b Increasing
concentration of sanguinarine was tested against reduced (circle) and oxidized (square) forms of PTP1B, using DiFMUP as substrate. c Increasing
concentration of levamisole was tested against reduced (circle) and oxidized (square) PTP1B, using DiFMUP as substrate. d PTP1B-OX (200 nM) was
incubated with sanguinarine (25 µM) for 5 min and the complex was diluted 100-fold and the activity was monitored for 120min continuously. e PTP1B-OX
(200 nM) was incubated with levamisole (40 µM) for 5 min and the complex was diluted 100-fold and the activity was monitored for 120min
continuously. f Increasing concentration of chelerythrine, an analog of sanguinarine, was tested against reduced (circle) and oxidized (square) forms of
PTP1B, using DiFMUP as substrate. A ki of 5 μM was calculated for PTP1B-OX and no apparent inhibition of the reduced form was detected. g Increasing
concentration of protopine, an analog of sanguinarine, was tested against reduced (circle) and oxidized (square) forms of PTP1B, using DiFMUP as
substrate. The compound did not inhibit the reduced or the oxidized form of the protein. Individual data points represent the mean obtained from three
separate experiments (n= 3; b–g)
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-02252-2 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:283 |DOI: 10.1038/s41467-017-02252-2 |www.nature.com/naturecommunications 7
marked change in the IC50 (Fig. 5b). Wild-type PTP1B-OX
displayed an IC50 of 5 μM for chelerythrine, whereas inhibition of
the K36A/K41A PTP1B-OX mutant was attenuated, with an IC50
of 75 μM for the same compound (Fig. 5b). We also tested single
mutants K36A, K41A, and N44A, but individually the differences
in the inhibitory potency were less noticeable.
These data suggest a putative binding site for chelerythrine that
overlaps with the site that was found to be critical for scFv45
binding (Figs. 1–3). This is also supported by the observation that
scFv antibodies with afﬁnities closer to that of chelerythrine were
able to compete with the small molecule for binding to PTP1B-
OX (Supplementary Fig. 11). The oxidized form of PTP1B-mut2,
in which Leu37, Lys39, and Lys41 in PTP1B were mutated to the
equivalent residues in TCPTP (L37F/K39E/K41R), did not bind
to scFv45, scFv67, and scFv106 (Fig. 1; Supplementary Fig. 11).
Interestingly, chelerythrine was also unable to inhibit reduction
and reactivation of the oxidized form of PTP1B-mut2 (Fig. 5c). In
addition, chelerythrine did not prevent complex formation
between PTP1B-OX and a thioredoxin substrate trapping
mutant24, suggesting that its effects were not simply due to
restricting access of reducing agents to the catalytic cysteine in
PTP1B (Supplementary Figs. 12 and 13). By comparing the
structures of the oxidized and reduced conformations of PTP1B,
we found that the residue Lys36 in PTP1B-OX moves and is
unable to H-bond to Arg47, unlike in reduced PTP1B. Thus, the
orientation of Lys36 may also be critical for chelerythrine binding
to PTP1B-OX (Fig. 5d). These data suggest that the chelerythrine-
binding site in PTP1B overlaps with that of scFv45 and provide
an explanation for the observed selectivity of the compound for
the oxidized form of the phosphatase.
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Chelerythrine enhanced insulin signaling in cells. We demon-
strated that chelerythrine sequestered reversibly oxidized PTP1B
and prevented reactivation of the enzyme. Furthermore, we
showed that a structurally related compound, protopine, had no
apparent effect on reduction and reactivation of PTP1B-OX.
Therefore, we tested the ability of the two compounds to
potentiate insulin signaling in 293T cells. When cells treated with
chelerythrine were stimulated with insulin, enhanced and sus-
tained phosphorylation of the insulin receptor β-subunit (IR-β)
was observed (Fig. 6a; Supplementary Fig. 14). We also tested the
effect of the compounds on downstream signaling; using a
phospho-speciﬁc antibody that recognizes the phosphorylation of
Thr308 in AKT, we observed that chelerythrine enhanced insulin-
induced activation of AKT. In contrast, when cells were treated
with protopine, there was no signiﬁcant effect on phosphorylation
of the insulin receptor or activation of AKT in response to insulin
stimulation (Fig. 6a). Upon overexpression of the H2O2-degrad-
ing enzyme catalase, the stimulatory effect of chelerythrine on IR-
β phosphorylation and AKT activation was ablated (Fig. 6b). This
important control demonstrated that insulin-induced ROS pro-
duction, and presumably PTP1B oxidation, was essential for the
effects of chelerythrine on insulin signaling. Furthermore, over-
expression of either PTP1B-wt or PTP1B-mut2 in 293T cells
attenuated insulin-induced phosphorylation of the β-subunit of
the insulin receptor to a similar extent (Supplementary Fig. 15).
In the presence of chelerythrine, we observed elevated insulin
signaling in control and PTP1B-wt expressing cells; in contrast,
cells expressing PTP1B-mut2 were insensitive to chelerythrine
(Supplementary Fig. 15). The data are consistent with PTP1B-OX
as the target of chelerythrine for its effects on insulin signaling in
these cells.
Leptin-induced oxidation of PTP1B augmented signaling.
Upon binding to its receptor, leptin induces phosphorylation and
activation of the protein tyrosine kinase JAK2, which initiates
downstream signaling responses25, whereas PTP1B has been
identiﬁed as an antagonist of JAK2 function26. In healthy liver,
hepatic stellate cells are in a quiescent state; however, following
injury, these cells become activated into myoﬁbroblasts that
produce extracellular matrix components, such as collagen,
resulting in ﬁbrosis27. There have been reports that leptin sig-
naling may contribute to this ﬁbrotic activity and that ROS
production is an important component of this signaling func-
tion28. Therefore, we used hepatic stellate cells as a model system
to test for leptin-induced oxidation of PTP1B.
We conﬁrmed that following treatment of hepatic stellate cells
with leptin there was elevated phosphorylation of JAK2
(Supplementary Fig. 16a). Furthermore, leptin administration
led to the production of ROS, in a dose- and time-dependent
manner (Supplementary Fig. 16b). Using scFv45 to immunopre-
cipitate PTP1B-OX, we demonstrated that leptin induced the
oxidation of PTP1B in hepatic stellate cells in a dose-dependent
manner (Fig. 7a). Ectopic expression of scFv45 led to enhanced
phosphorylation of JAK2 in response to leptin (Fig. 7b).
Furthermore, this stimulatory effect was abrogated by treatment
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with apocynin, which as an inhibitor of NOX (NADPH Oxidase)
attenuates ROS production (Fig. 7c). With this in mind, we tested
the effects of cheleryrthrine in stellate cells to assess the extent to
which it mimicked the effects of scFv45. We observed that
chelerythrine treatment induced a dose-dependent increase in
tyrosine phosphorylation of JAK2 (Fig. 7d) and that these effects
were attenuated by inclusion of apocynin (Fig. 7e). These results
illustrate that, similar to insulin signaling, the response to leptin
may be ﬁne-tuned by reversible oxidation and inactivation of the
negative regulator PTP1B. Furthermore, they suggest that by
stabilizing PTP1B-OX, chelerythrine may be able both to improve
glucose homeostasis and reverse obesity induced by a high fat
diet.
Chelerythrine improved metabolism in high fat diet-fed mice.
To test this hypothesis, we used high fat diet-fed C57Bl6/J mice to
examine the effects of chelerythrine on metabolism in animals. As
a ﬁrst step, we established that PTP1B was present in an oxidized
state. Using scFv45 as a probe, we demonstrated that adminis-
tration of insulin or leptin to chow-fed animals led to elevated
oxidation of PTP1B in liver and hypothalamus, respectively
(Fig. 8a). Furthermore, the level of PTP1B-OX was elevated
~2.5-fold in high fat diet-fed animals compared to those on a
normal chow diet (Fig. 8b).
We treated high fat diet- and chow diet-fed mice with
chelerythrine, protopine or saline. In contrast to saline,
chelerythrine-treated, high fat diet-fed mice started losing weight
within a week of treatment. The weight loss continued for about
14 days, after which no signiﬁcant decrease in body weight was
observed. Overall, we observed ~3% decrease in body weight with
chelerythrine (Fig. 9a). Furthermore, no signiﬁcant change in
body weight was observed with chelerythrine-treated mice fed a
chow diet, suggesting the weight loss observed is a consequence of
improved metabolism in the obese model. Interestingly, weight
loss was not observed in protopine-treated mice. This is
consistent with the inability of protopine to elicit any inhibitory
effect on either reduced or oxidized PTP1B, and suggests that the
effects of chelerythrine resulted from stabilization of PTP1B-OX.
Furthermore, we demonstrated that, in contrast to saline or
protopine treatment, chelerythrine improved glucose tolerance
and insulin sensitivity in glucose and insulin tolerance tests
(Fig. 9b, c; Supplementary Fig. 17).
These data suggest that cheleythrine led to enhanced insulin
signaling in the high fat diet-fed mice. To examine this further, we
measured the effect of the compound on tyrosine phosphorylation
of the insulin receptor β-subunit and activation of downstream
signaling, through phosphorylation of AKT in the liver. We
observed that there was a marked increase in IR-β phosphoryla-
tion following chelerythrine treatment, which was not observed
with saline or protopine (Fig. 9d). Consistent with this, we
observed enhanced AKT phosphorylation with chelerythrine
treatment, indicating improved insulin signaling in response to
the compound (Fig. 9d). Considering also the important role of
leptin in the control of glucose homeostasis and obesity29,30, we
tested the effects of the compounds on leptin signaling in the
hypothalamus. Similar to the improvement in insulin signaling, we
observed that chelerythrine treatment, but not saline or protopine,
led to enhanced phosphorylation of JAK2 (Fig. 9e).
Discussion
Dietary and lifestyle changes that began to appear in the latter
part of the last century have contributed to a global epidemic in
obesity, which underlies a dramatic increase in cases of type 2
diabetes and associated cardiovascular complications. The
resulting loss of normal control of blood glucose levels in these
conditions represents a huge challenge for healthcare systems
worldwide. A greater awareness of the “prediabetic” state has
prompted many to embrace changes in diet and exercise that help
to restore normal control of glucose homeostasis before the
development of full-blown diabetes; however, on its own this is
insufﬁcient and therapeutic options are required. Metformin is a
ﬁrst line medication that addresses elevated blood glucose,
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although it does present gastrointestinal complications. Sulfony-
lureas are also established therapies to promote insulin produc-
tion, but they are associated with risk of hypoglycemia.
Thiazolidinediones, such as rosiglitazone, which function as
PPAR (peroxisome proliferator-activated receptor) agonists, are
associated with weight gain and increased risk of heart failure.
More recently, SGLT2 (sodium-glucose transporter 2) inhibitors
were shown to promote a decrease in blood glucose due to
increased excretion through the kidneys, although there have
been indications of increased risk of diabetic ketoacidosis and
urinary tract infections1,31. Overall, there are several treatment
options currently available, but they are associated with sig-
niﬁcant side effects and the incidence of diabetes and obesity
continues to rise. Consequently, novel therapeutic approaches are
required.
The effects of insulin and leptin are coordinated for control of
whole-body glucose homeostasis and energy balance. Insulin,
produced by the pancreas, regulates glucose uptake into muscle
and other tissues, through activation of speciﬁc transporters, with
the effect of controlling glucose levels in the blood32. In addition,
it promotes glucose storage in the liver as glycogen, as well as
promoting fatty acid synthesis. Leptin, which is produced by
adipose tissue, is a major regulator of food intake and energy
expenditure30,33. In addition, it contributes to maintaining glu-
cose homeostasis30. Insulin exerts its effects by binding to the
insulin receptor protein tyrosine kinase and initiating signaling
pathways, in particular, those leading to phosphorylation and
activation of AKT34. Leptin also functions through tyrosine
phosphorylation-dependent signaling, in this case through acti-
vation of a receptor-associated kinase, JAK226. Diabetes and
obesity are diseases of insulin and leptin resistance, in which the
signaling responses to the hormones are attenuated. Therefore, an
ideal therapeutic target would be one that serves as a negative
regulator of both signaling pathways, inhibition of which could
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chelerythrine were administered D-glucose (2 mg g−1 body weight), and blood glucose was monitored over the deﬁned time. Data represent the mean± s.e.
m. (n= 10 in each group) and statistical analysis was performed using two-way ANOVA (*p< 0.05, **p< 0.01). c HFD fed 14-week-old male mice treated
with saline or chelerythrine were administered insulin (0.75mU g−1 body weight), and blood glucose was monitored over the deﬁned time. Data represent
mean± s.e.m. (n= 10 in each group) and statistical analysis was performed using two-way ANOVA (*p< 0.05). d Representative immunoblots showing
insulin-induced tyrosine phosphorylation of IR-β and phosphorylation of AKT, and their corresponding total protein levels, in liver tissue lysates from 14-
week-old male mice treated with saline, chelerythrine or protopine. For insulin stimulation, animals were treated with insulin (0.75mU g−1, i.p.) for 15 min. e
Representative immunoblots showing leptin-induced tyrosine phosphorylation of JAK2 and corresponding total JAK2 levels in the hypothalamus tissue
lysates from 14-week-old male mice treated with saline, chelerythrine or protopine. For leptin stimulation, animals were treated with leptin (1 mg kg−1, s.c.)
for 15 min. All immunoblots are representative of tissue lysates generated from at least three independent animals for each condition (n= 3). Immunoblots
were quantiﬁed using ImageJ software. Quantitation includes all independent data from the respective experiments and is presented as the mean± s.e.m.
d, e Statistical analysis was performed using two-way ANOVA (*p< 0.05)
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restore a normal hormonal response. PTP1B is one such target
that counters the tyrosine phosphorylation events that promote
insulin and leptin signaling and may address simultaneously
issues of excess weight and disrupted glycemic control.
Gene targeting studies demonstrated that PTP1B-null mice are
healthy, display enhanced insulin sensitivity, do not develop type
2 diabetes and are resistant to obesity when fed a high fat diet6.
Consequently, many programs were established in the pharma-
ceutical industry to generate small molecule inhibitors of PTP1B.
Although potent, speciﬁc and reversible active site-directed
inhibitors of PTP1B were developed, their high afﬁnity depends
upon charge, which limits their bioavailability and drug devel-
opment potential. Consequently, industry views PTPs as chal-
lenging targets. Innovative approaches are required to generate
inhibitors of this highly validated target that exhibit greater drug
development potential. To try to meet this challenge, we have
adopted a novel strategy that exploits a physiological mechanism
for regulation of PTP function. Previously, we and others
demonstrated that PTP1B is transiently oxidized in response to
insulin signaling, and this modiﬁcation is important for the
optimal activation of the insulin receptor tyrosine kinase16,17. We
found that reversible oxidation induced profound conformational
changes in PTP1B, which present new binding surfaces that are
unique to the reversibly oxidized form of the protein. We
exploited this to generate recombinant antibodies, such as the
intrabody scFv45, to trap PTP1B-OX in the catalytically inactive
form17. We have demonstrated that sequestering PTP1B in the
oxidized, inactive state can promote insulin signaling in cells. In
this study, we have now demonstrated redox regulation of PTP1B
function also in response to leptin signaling. Furthermore,
expression of scFv45 led to enhanced leptin signaling in a hepatic
stellate cell model. These data suggest that a small molecule
scFv45-mimetic that can bind and stabilize PTP1B-OX in its
inactive state may enhance both insulin and leptin sensitivity, and
thus may underlie a viable therapeutic approach to treatment of
diabetes and obesity.
By applying several complementary strategies, we have gener-
ated an understanding at a molecular level of the interaction
between scFv45 and PTP1B-OX. Previous drug development
efforts targeting the active site of PTP1B were hampered by cross
reactivity with the closely related paralogue TCPTP. In contrast to
PTP1B-null mice, homozygous deletion of TCPTP is lethal due to
a systemic inﬂammatory disease35. Therefore, despite the ability
of TCPTP also to regulate insulin and leptin signaling36,37, drug
discovery efforts have focused on inhibitors that are speciﬁc for
PTP1B over TCPTP. A striking feature of scFv45 is its speciﬁcity
for PTP1B-OX; it does not bind to TCPTP in either oxidized or
reduced states17. Our analysis demonstrates that a cluster of basic
residues unique to PTP1B over TCPTP were required for inter-
action with acidic residues in the complementarity-determining
regions of those scFv constructs that bound to the oxidized form
of the phosphatase. Our small molecule screen identiﬁed san-
guinarine, and ultimately chelerythrine, as inhibitors that func-
tioned also by stabilizing PTP1B-OX; these small molecules
demonstrated similar speciﬁcity to scFv45 and appear to interact
with an overlapping site in the phosphatase.
Chelerythrine displayed remarkable speciﬁcity in its interaction
with PTP1B. In assays in vitro, it was selective for stabilization of
the oxidized form of the enzyme, but did not inhibit the reduced,
active form of PTP1B. These effects were seen with both TCEP
(thiol-free) and DTT (thiol-dependent), suggesting that its effects
were not exerted indirectly through compromising the function of
the reducing agent. Furthermore, mutation of basic residues in
PTP1B, to generate PTP1B-mut2 (Fig. 1a), produced a form of
the phosphatase that was insensitive to chelerythrine (Fig. 5c),
again pointing to a direct effect on the enzyme rather than a non-
speciﬁc effect, such as aggregation. Finally, the fact that, unlike
chelerythrine, the closely related molecule protopine did not
stabilize PTP1B-OX further reinforces the speciﬁcity of this
association. Nevertheless, chelerythrine has been reported to act
on other targets in the cell. Most notably, there have been several
reports that it is an inhibitor of PKC38; however, more recently,
this has been called into question39,40. Furthermore, the related
molecule sanguinarine, which was the initial hit in our LOPAC
library screen, is not an inhibitor of PKC41. In our cell-based
studies, the effects of chelerythrine on insulin signaling in
293T cells were abrogated by expression of catalase. Similarly, its
effects on leptin signaling in hepatic stellate cells were attenuated
by the NOX-antagonist apocynin (Fig. 7e), indicative of the
importance of ROS production for the effects of the compound.
Consistent with this mechanism of action, antioxidants were
reported to block the effects of chelerythrine on shedding of
heparin-binding EGF42 and the activation of JNK and p3843.
Therefore this work suggests a new target and mechanism of
action for the compound, especially in the context of insulin and
leptin resistance.
Consistent with the demonstration that obesity is associated
with reversible PTP oxidation in the liver44, our study revealed
that PTP1B was reversibly oxidized in response to insulin and
leptin administration to animals fed a chow diet and that the
levels of PTP1B-OX were elevated in the high fat diet-fed mouse
model of obesity (Fig. 8a, b). In addition to its effects in cells, our
studies demonstrated that chelerythrine promoted signaling in
response to insulin and leptin, enhanced glucose homeostasis and
promoted weight loss in high fat diet-fed mice (Fig. 9). Overall,
our data are consistent with a model in which chelerythrine
stabilizes the oxidized form of PTP1B in the obese animals,
thereby promoting whole-body glucose homeostasis. In addition
to targeting PTP1B-OX speciﬁcally over TCPTP, it is important
to note that this approach will only target the pool of PTP1B that
is susceptible to reversible oxidation and inactivation. Pre-
sumably, because this is the pool of the phosphatase that has been
selected for acute regulation in response to hormone, this is also
the critical pool of PTP1B that is important for regulation of
downstream signaling. Consequently, this strategy may decrease
any side effects that would result from targeting the total pool of
PTP1B.
Overall, our study illustrates a strategy to target therapeutically
a major signaling enzyme that is considered by the pharmaceu-
tical industry to be too difﬁcult to inhibit with active site-directed
small molecules. Our intrabody-guided development of a func-
tional high-throughput screening assay provides proof-of-concept
in identifying small molecule mimetics as an approach to early
stage drug discovery. The structural attributes of scFv45 binding
can be further applied to reﬁne future drug development efforts
through analysis of CDR-mimetic pharmacophores. It is impor-
tant to note that although chelerythrine itself is unlikely to be a
drug candidate, we hope that this platform may serve as a starting
point for the development of novel, more potent and drug-like
molecules with which to address this major unmet medical need.
Methods
Reagents. All common reagents were obtained from Thermo Fisher Scientiﬁc
(Waltham, MA) or Sigma-Aldrich (St. Louis, MO). Diﬂuoro-4-methylumbelliferyl
phosphate (DiFMUP) was obtained from Invitrogen (cat # D22065). The solid
black 384-well plates (cat# 3573) for the compound screening assay were from
Corning Incorporated (Corning, NY). The LOPAC compound Library was
obtained from Sigma-Aldrich (St. Louis, MO).
Antibodies. The antibodies used in the study: mouse monoclonal anti-
phosphotyrosine antibody (catalog 05–321, clone 4G10; Millipore); anti-pY1162/
1163-IR-β (catalog 700393, clone 97H9L7; Invitrogen); anti-IR-β (catalog sc-711,
clone C711; Santa Cruz Biotechnology Inc.); anti-actin (catalog A2228, clone AC-
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74, Sigma-Aldrich); anti-p-T308 AKT (catalog 13038, clone D25E6; Cell Signaling
Tech), anti-AKT (catalog 4691, clone C67E7; Cell Signaling Tech), anti-JAK2
(catalog 3230, clone D2E12; Cell Signaling Tech); anti-catalase (catalog ab16731;
abcam), anti-HA (catalog 11583816001, clone 12CA5; Roche), and anti-PTP1B
(EP1841Y; abcam). Antibodies were used at dilutions recommended by the
manufacturers.
Site-directed mutagenesis. Site-directed mutagenesis was performed using
QuikChange multisite-directed mutagenesis kit (Stratagene) as per manufacturers
protocol. PTP1B (1–321) and TCPTP (1–317) cloned in pET21b vector were used
as templates to generate -mut1 and -mut2 mutant plasmids, respectively. The
PTP1B-mut1 construct was generated using TTACCAGGATATCCGA-
CATGAAGCCCATGACTATCCACATAGAGAGGCCAAGCTTCCTAAGAAC
as forward and GTTCTTAGGAAGCTTGGCCACTCTATGTGGA-
TAGTCATGGGCTTCATGTCGGATATCCTGGTAA as reverse primers. PTP1B-
mut2 construct was generated using CCATGTAGAGTGGCCAAGTTTCCTGA-
GAACAGAAACCAAATAGGTACAG as forward and CTGTACC-
TATTTCGGTTTCTGTTCTCAGGAAACTTGGCCACTCTACATGG as reverse
primers. The TCPTP-mut1 construct was generated using GTACTTG-
GAAATTCGAAATGAGTCCAGTGACTTTCCTTGTA-
GAGTGGCCAAGTTTCCAGAAAAC as forward and
GTTTTCTGGAAACTTGGCCACTCTA-
CAAGGAAAGTCACTGGACTCATTTCGAATTTCCAAGTAC as reverse pri-
mers. TCPTP-mut2 construct was generated using
TATCCTCATAGAGTGGCCAAGTTACCAAAAAACAAAAATCGAAACAGA-
TACAGAGAGATG as forward and CATCTCTGTATCTGTTTC-
GATTTTTGTTTTTTGGTAACTTGGCCACTCTATGAGGATA as reverse
primers.
Puriﬁcation of wild-type and mutant PTP1B and TCPTP. Wild-type and mutant
forms of PTP1B and TCPTP containing a 6xHis-tag were expressed in BL21
(DE3)-RIL Escherichia coli using LB. Cells were resuspended in lysis buffer (50 mM
Hepes pH 7.2, 150 mM NaCl, 10 mM imidazole, 2 mM TCEP) containing cOm-
plete EDTA-free Protease Inhibitor Cocktail (Roche), and then lysed using soni-
cation at 4 °C. Lysates were clariﬁed by centrifugation, with subsequent protein
puriﬁcation performed by gravity ﬂow using Ni-NTA (Qiagen) column chroma-
tography. Protein was further puriﬁed using an AKTA FPLC connected to a
HiLoad 16/600 Superdex 75 pg size-exclusion chromatography column (GE
Healthcare Life Sciences) into 50 mM HEPES pH 7.4, 100 mM NaCl, and 2 mM
dithiothreitol. Protein was used immediately or stored at −80 °C in in 50 mM
HEPES pH 7.4, 100 mM NaCl, 2 mM dithiothreitol, and 25% glycerol.
PTP1B oxidation and reactivation. Puriﬁed PTP1B (1–321) (100 nM) was mixed
with increasing concentrations of H2O2 (0.05–100 mM) in phosphatase assay
buffer (50 mM HEPES, pH 7.0, 100 mM NaCl, 0.1% BSA) at room temperature for
5 min. From this reaction mixture PTP1B (10 nM) was used to monitor phos-
phatase activity using DiFMUP as the substrate, with or without 5 mM TCEP.
Activity of each sample was compared to that of the untreated PTP1B in the
presence of 5 mM TCEP.
Binding assay. To demonstrate interaction between wild-type (wt) and mutant
forms of PTP1B-OX or TCPTP-OX and scFv45, we performed an in vitro binding
assay using puriﬁed recombinant proteins. Puriﬁed proteins (wt or mutant form of
PTP1B or TCPTP (50 nM)) were reversibly oxidized with 250 mM H2O2 followed
by a buffer exchange using 0.5 mL Zeba spin desalting columns 7K MWCO
(Thermo Fisher Scientiﬁc) to remove H2O2. Increasing concentration of puriﬁed
HA-tagged scFv45 (0–10 µM) was incubated with oxidized proteins in binding
buffer (20 mM HEPES, pH 7.4, 300 mM NaCl, 0.05% BSA, 0.05% Tween-20) for 2
h at 4 °C. Anti-HA agarose (Roche, 50% slurry equilibrated in the binding buffer)
was added and incubated for 1 h at 4 °C. Protein complexes bound to anti-HA
beads were immunoprecipitated and washed three times; ﬁrst with lysis buffer
followed by two more washes with wash buffer (25 mM HEPES, 100 mM NaCl pH
7.4, 0.05% BSA, 0.05% Tween-20, and protease inhibitors). The complexes were
separated by SDS-PAGE and analyzed by immunoblotting.
Analytical size-exclusion chromatography. Recombinant PTP1B-CASA, PTP1B-
CASA-mut2, and scFv45 were puriﬁed as described. Proteins were exchanged into
freshly prepared 50 mM ammonium bicarbonate pH 8 (Fig. 2a; Supplementary
Fig. 1) using 0.5 mL Zeba spin desalting columns 7K MWCO (Thermo Fisher
Scientiﬁc) as per manufacturers protocol. Designated protein constructs or buffer
equivalents were mixed at 1.1 or 1.4 molar excess (excess reciprocated for both
PTP1B and scFv45) and incubated on ice 20 min prior to injection (20 µL injection
loop; 4–10 µg total protein), separation, and detection on a Dionex Ultimate 3000
HPLC connected to an XBridge Protein BEH SEC 200 Å, 3.5 µm, 7.8 mm × 300 mm
column (Waters) ﬂowing 200 mM ammonium acetate pH 7.0 isocratically at 0.86
mLmin−1 and 25 °C, monitoring absorbance at λ 280 nm (Fig. 2a; Supplementary
Fig. 1). Injections were performed intermittently with BEH200Å SEC Protein
Standard Mix (amount corrected for 20 µL injection loop; Waters Corp.) to
monitor peak resolution and retention time consistency among runs.
Size-exclusion chromatography. Recombinant PTP1B-CASA, TCPTP-CASA,
TCPTP-CASA-mut2, and scFv45 were puriﬁed as described. Proteins were
exchanged into freshly prepared 50 mM HEPES pH 7.4, 100 mM NaCl, 2 mM
DTT, 20% glycerol (Supplementary Fig. 2) using 0.5 mL Zeba spin desalting col-
umns 7K MWCO (Thermo Fisher Scientiﬁc) as per manufacturers protocol.
Designated protein constructs or buffer equivalents were mixed at 1.1 molar excess
of scFv45 to TCPTP and incubated on ice 20 min prior to injection (200 µL
injection loop; 200–420 µg total protein), separation, and detection on an AKTA
FPLC connected to a HiLoad 16/600 Superdex 75 pg SEC column (GE Healthcare
Life Sciences) ﬂowing 10 mM HEPES pH 7.4, 100 mM NaCl isocratically at 1 mL
min−1 and 4 °C, monitoring absorbance at λ 280 nm, collecting 1 mL fractions
(Supplementary Fig. 2). Designated protein fractions were mixed 4:1 with reducing
6× SDS loading dye, resolved by SDS-PAGE, and proteins visualized by Imperial
Protein Stain coomassie dye R-250 (Thermo Fisher Scientiﬁc). Quantiﬁcation of
protein staining was performed with ImageJ software, with protein staining of
target fractions being normalized to protein staining of internal loading controls
(0.2 µg; lanes 2 and 9) in relation to staining of target protein standard curves
(0.2–1.6 µg; Supplementary Fig. 2b, c).
Protease protection assay. Recombinant PTP1B-CASA, PTP1B-CASA-mut2,
and scFv45 were exchanged into freshly prepared 50 mM ammonium bicarbonate
pH 8 as described above. Designated protein constructs were mixed at a 1.1-fold
molar excess of scFv45 or buffer equivalent (0.3 µg µL−1 PTP1B or 0.24 µg µL−1
scFv45, respectively) and incubated as above prior to addition of AspN or LysC
endoprotease at 1:500 (w/w) or 1:750 (w/w), respectively. Digests proceeded at 25 °
C with aliquots being taken at designated time points (0, 15, 30, 60, 120, 240, and
480 min) and quenched by addition of Complete protease inhibitor cocktail with
EDTA (Roche) to a ﬁnal concentration of 5×. Quenched protein digests were
mixed 1:2 with reducing 3× SDS loading dye, resolved by SDS-PAGE, and visua-
lized as described above (Supplementary Fig. 5). Alternatively, quenched protein
digests were mixed 1:1 with either 50 mM ammonium bicarbonate pH 8 (for
PTP1B: scFv45 complex digests) or with the corresponding digest of scFv45-alone
(for digests of PTP1B-alone) to equate both total buffer salt and total protein
content across all samples. Samples were then mixed 1:4 with 65% acetonitrile
(ACN), 0.1% triﬂuoroacetic acid (TFA) and spotted 1:1 (at 1 µL) with 10 mgmL−1
recrystallized α-cyano-4-hydroxy-cinnamic acid matrix (Thermo Fisher Scientiﬁc)
dissolved in 65% ACN, 0.1% TFA onto a stainless steel target by the dried-droplet
method. Above samples mixed 1:4 with 65% ACN, 0.1% TFA from LysC digestion,
were further mixed 4:1 with an approximate average of 212.5 fmol µL−1 internal
peptide mass standard calibration mixture 2 (AB Sciex) dissolved in 65% ACN,
0.1% TFA, and spotted onto the target plate as described above. To eliminate the
inherent bias in spectral acquisition among sample spots due to manual targeting
of optimal co-crystals, peptide mass ﬁngerprints of protein digests were analyzed
by matrix assisted laser desorption ionization-time of ﬂight mass spectrometry
(MALDI-TOF MS) in positive ion mode using either the automated linear or
automated reﬂector mode on an Applied Biosystems Voyager DE-Pro Mass
Spectrometer. For each instrument mode and sample condition, the attenuated
laser intensity (ranging 1700–1810), extraction delay time (ranging 120–250 nsec),
and number of laser shots per spectrum (ranging 250–500), were manually opti-
mized and remained constant throughout the entirety of each comparable analysis,
as were all other instrumental parameters. Each spot was analyzed randomly with a
center-bias to ensure that acquired spectra (5–10 per sample spot) were measured
from within the droplet boundaries of formed co-crystals, culminating to
140–280 spectral replicates per proteolytic condition (AspN or LysC). Each
acquired spectra was individually curated and selected for display based on near
average absolute and relative ion intensities, optimal signal-to-noise ratios, and
equivalency of these parameters among conditions to be compared. Spectra were
baseline corrected and mass calibrated with internal peptides of known identities
and masses using the Data Explorer software (Applied Biosystems) (Fig. 2b, c;
Supplementary Figs. 3a and 4a). Mass spectral measurements and processing, as
outlined above, were obtained from at least two independent experiments for each
proteolytic condition. Tandem mass spectrometry (MS/MS) of target ions was
performed manually using post-source decay, with spectra being acquired in
10–15 segments of mirror ratios ranging from 0.1 to 1.0. Segments were compiled
into single spectra, baseline corrected, and noise ﬁltered using Data Explorer
software (Applied Biosystems) and compared to in silico fragmentation using the
Protein Prospector software (http://prospector.ucsf.edu/) (Supplementary Figs. 3b
and 4b).
Expression and puriﬁcation of the intrabody scFv45. Recombinant scFv45 was
puriﬁed similar to previously described methods17. Brieﬂy, 6xHis-tagged scFv45
was expressed in BL21 (DE3)-RIL Escherichia coli using LB. Cells were resuspended
in lysis buffer (50 mM Tris pH 7.5, 250 mM NaCl, 10 mM imidazole) containing
cOmplete EDTA-free Protease Inhibitor Cocktail (Roche), then lysed by sonication
at 4 °C. Lysates were clariﬁed by centrifugation, with initial protein puriﬁcation
being performed by gravity ﬂow using Ni-NTA column chromatography. The
6xHis-tag of scFv45 was removed by proteolysis using recombinant 6xHis-tagged
rTEV protease overnight at 4 °C. Uncleaved scFv45-6xHis, cleaved 6xHis-tag, and
the 6xHis-tagged rTEV were all separated from cleaved, untagged scFv45 by gravity
ﬂow using Ni-NTA column chromatography as above. Protein was further puriﬁed
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using an AKTA FPLC connected to a HiLoad 16/600 Superdex 75 pg size-exclusion
chromatography column (GE Healthcare Life Sciences) in 50 mM HEPES pH 7.4,
100 mM NaCl, and 2 mM dithiothreitol as above. Protein was used immediately or
stored at −80 °C.
Structure determination and reﬁnement. Initial crystal screening was performed
using soluble screen at the High-throughput Crystallization Screening lab (HTSlab)
at Hauptman-Woodward Medical Research Institute45. Crystals were obtained at 4
°C by the sitting drop vapor-diffusion method. Two hundred nl of scFv45 (13 mg
ml−1) was mixed with 200 nl of crystallization buffer (0.1 M CAPS pH 10.0, 0.1 M
Ammonium Chloride, 40% PEG 400) and placed over a reservoir of 300 μl in
volume. scFv45 protein crystals reached a size of 80 × 20 microns within a week.
Crystals were ﬂash-frozen in liquid nitrogen directly from the crystal drop. X-ray
diffraction data were collected at 100 K at Keck Structural Biology Laboratory using
Rigaku MicroMax-007HF at a wavelength of 1.54178 Å. Data were processed using
XDS46. The structure of scFv45 was solved by molecular replacement with Phaser47
using chicken scFv structure, (PDB ID: 4P49)48 as a search model, with one
molecule in the asymmetric unit. Initially, model building used Autobuild47, fol-
lowed by manual model building using Coot49. Structure reﬁnement was per-
formed with Phenix.reﬁne47 using the individual B-factors and occupancies. Water
molecules were added during Autobuild47 and manually using Coot49.
Ramachandran-plot analysis, carried out with MolProbity50, showed that 97.30% of
the residues were in favored regions; 100% were in allowed regions. For repre-
sentative numbering of scFv45 residues, the ﬁrst amino acid denotes the residue
directly following the OmpA cleavage site.
LOPAC screen. To screen the LOPAC library against PTP1B-OX, 0.5 μl of 1 mM
compound in 100% DMSO was added to 384-well plates, resulting in a ﬁnal
compound concentration of 10 μM for the primary screen. Recombinant PTP1B
(100 nM) was reversibly oxidized and inactivated with H2O2 (4 mM). The phos-
phatase activity was restored by a quick buffer exchange and addition of reducing
agent (TCEP). PTP1B-OX was incubated with LOPAC compounds (10 μM) in the
assay buffer (50 mM HEPES pH 7.0, 100 mM NaCl, 0.005% Tween, 2 mM EDTA)
and the effect of individual compound on stabilizing the reversibly oxidized con-
formation was assessed by the phosphatase assay under reducing conditions using
DiFMUP as substrate. scFv45 was used as positive control. Z′-factor values were
always between 0.6 and 0.8 indicating that the assay is robust.
Isothermal titration calorimetry. The studies were performed using a VP-ITC
system from GE Healthcare. All titrations were performed at 25°C in de-gassed
buffer (50 mM HEPES pH 7.0, 100 mM NaCl, 2 % DMSO, and 1 mM TCEP). The
protein concentrations of PTP1B-CASA and PTP1B-CASA-mut2 were each 50
μM. Protein samples used in ITC were dialyzed completely against the buffer.
Inhibitor (10 mM) in DMSO was diluted to make a stock solution of 0.2 mM in de-
gassed buffer, which was then used as titrant in the syringe. The instrument was
calibrated by using the heat of dilution of NaCl in water. By titrating buffer into
protein solution the heat generated due to protein dilution was estimated and was
found to be negligible. The heat of ligand dilution was corrected by subtracting the
average heat of injection after saturation. Origin software was used to ﬁt and
analyze the data.
The data in Supplementary Fig. 9 are representative of three independent
experiments for PTP1B-CASA, in which the afﬁnities were measured as 3.25±
0.36, 2.83 ± 0.15, and 3.44 ± 0.23 micromolar, and two independent experiments
for PTP1B-CASA-mut2, in which we did not detect saturable binding.
Molecular modeling. Protein and Ligand Preparation: Within Schrödinger’s
Maestro interface, the Protein Prep Wizard was applied to process the following
pdb structures: 1OEM (PTP1B-OX), 1A5Y (PTP1B, closed form), and 1T4J
(PTP1B, open form). The enzymes were treated to correct any mismatched bonds,
add missing hydrogens, remove bulk water, and assign atom types, bond orders
and atomic partial charges. In addition, a simple minimization was performed in
this step using the OPLS2005 force ﬁeld to a default RMSD of 0.3 Å. Levamisole,
sanguinarine, and chelerythrine were minimized (50 iterations per input structure,
SD method), and a set of low-energy conformations were obtained for each using
the LigPrep tool and the OPLS2005 force ﬁeld. LigPrep generates atom types and
other parameters speciﬁc for the Glide module; in addition, alternate tautomers,
ionization states, and ring geometries are sampled to broaden the sets of ligand
input conformations for docking.
SiteMap: Site map begins with an initial search that identiﬁes potential
superﬁcial small molecule binding sites on the enzyme by using a grid of “site
points.” Next, contour maps are produced that include donor, acceptor, and
hydrophobic pocket regions within the sites. A SiteScore is obtained that
incorporates some of the following properties: “the size of the site; the degrees of
enclosure by the protein and exposure to solvent; the tightness with which the site
points interact with the receptor; the hydrophobic and hydrophilic character of the
site and the balance between them; the degree to which a ligand might donate or
accept hydrogen bonds.” (Ref: Schrödinger 2016-1 SiteMap User Manual).
The SiteScore is deﬁned as follows:
SiteScore ¼ 0:0733p nð Þ þ 0:6688 e0:20p
where, n = number of site points (100 max), e is the enclosure score, and p is the
hydrophilic score. A SiteScore >1 is considered signiﬁcant and worthy of
consideration as a potential binding site (Ref: Schrödinger 2016-1 SiteMap User
Manual). Five top-scoring sites were identiﬁed for 1OEM, 1A5Y, and 1T4J,
respectively.
Glide docking: The docked models of 1OEM and levamisole, sanguinarine, and
chelerythrine were generated with the Glide module. In the initial step of Glide
docking, a grid was constructed within the receptor, deﬁning the binding site and
accounting for potential Van der Waals, polar, and charged interactions. For
1OEM, the centroid of site 5 was deﬁned as the “ligand” for grid generation with a
default “inner box” of 10 Å3 and an “outer box” of 26 Å3. Levamisole, sanguinarine,
and chelerythrine were docked ﬂexibly within the grid in SP mode for initial model
development.
Poses were ranked with the GlideScore function:
GScore ¼ 0:065  vDWþ 0:130  Coulþ LipoþHBond
þMetalþ BuryPþ RotBþ Site:
Restrained minimization: A restrained minimization was performed for
chelerythrine to identify whether hydrogen bond contacts may be made between
the methoxy oxygen atoms of chelerythrine and amine atoms of key residues K41,
N44, and R45. These residues do not appear to be involved in structural stability or
to impact the conformation of the enzyme. The distances between the proposed
interacting atoms was set at 4 Å, and after 25,000 iterations using the PRCG
method, set to converge on movement at 0.005 convergence threshold, the
minimization concluded successfully. Chelerythrine and Y46 were held ﬁxed
during the calculation. No severe distortions were observed in the enzyme
structure.
Software references: Schrödinger’s 2015–3 and 2016–7 Small Molecule Drug
Discovery Suite: Maestro v10.3, v10.9; Macromodel v10.7, v11.1; Glide v6.8,
v70014; SiteMap v3.4.013. Schrödinger, LLC: New York, NY, 2015, 2016.
Displacement assays. To test whether there was overlap in the binding site for
chelerythrine and scFv antibodies that stabilized PTP1B-OX, we performed an
in vitro competition binding assay using puriﬁed components. The antibody
scFv45 displays nanomolar afﬁnity for PTP1B-OX; therefore, we characterized
additional scFvs to identify antibodies with micromolar afﬁnities for PTP1B-OX,
closer to that of chelerythrine. We focused on scFv106 and scFv67. Puriﬁed PTP1B
(50 nM) was reversibly oxidized with 250 µM H2O2 followed by a buffer exchange
to remove excess H2O2. Increasing concentration of puriﬁed scFv antibody (0–10
µM) was incubated with oxidized proteins in binding buffer (20 mM HEPES pH
7.4, 300 mM NaCl, 0.05% BSA, 0.05% Tween-20) for 2 h at 4 °C. Anti-HA agarose
(Roche, 50% slurry equilibrated in the binding buffer) was added and incubated for
1 h at 4 °C. Protein complexes bound to anti-HA beads were precipitated and
washed three times; ﬁrst with lysis buffer followed by two more washes with wash
buffer (25 mM HEPES pH 7.4, 100 mM NaCl, 0.05% BSA, 0.05% Tween-20, and
protease inhibitors). The protein complex was incubated with varying concentra-
tions of chelerythrine (0–20 µM) for 2 h at 4 °C, following which the beads were
washed as described above. The complexes were resolved by SDS-PAGE and
analyzed by immunoblotting.
In vitro substrate trapping of PTP1B by Trx1 mutant variants. Thioredoxin
(TRX), which functions to reduce oxidized cysteines in target proteins, contains an
essential CXXC motif, in which the ﬁrst cysteine forms a mixed disulﬁde inter-
mediate with an oxidized cysteine in the target protein. The second cysteine then
serves a “resolving” function—it forms a disulﬁde bond with the ﬁrst cysteine in the
CXXC motif, with the resulting transfer of electrons leading to reduction of the
target protein. We utilized an assay using a “trapping mutant” form of thioredoxin
in which the second cysteine is mutated to serine, which stabilizes the mixed
disulﬁde intermediate with the target substrate.
Recombinant variants of N-terminally His-tagged human TRX1 (0.1 mg, WT,
and trapping mutant, C35S) were reduced with 20 mM DTT in 1 mL PBS on ice for
30 min, then desalted on a Sephadex PD-10 column. Ten μg each of TRX1-WT and
TRX1-C35S proteins was used in the trapping experiment. PTP1B (40 μg ml−1) was
incubated with H2O2 (0, 0.1 and 0.5 mM) for 10 min at room temperature and
excess H2O2 was removed by desalting. Reduced and oxidized forms of PTP1B (20
μg) were incubated with WT or trapping mutant TRX1 for 20 min at room
temperature in the absence and presence of chelerythrine (5 μM) in 1 mL PBS. Ni-
NTA beads were added and incubated for 1 h at 4 °C. Protein complexes bound to
Ni-NTA beads were washed three times with PBS (pH 7.4) containing 40 mM
Imidazole, 0.05% BSA, 0.05% Tween-20, and protease inhibitors. The complexes
were resolved by SDS-PAGE and blotted for PTP1B (FG6) and TRX1 (sc-58439,
Santa Cruz Biotechnology).
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Insulin signaling in HEK 293T cells. To study the effect of chelerythrine and
protopine on insulin signaling we used 293T cells (ATCC) and cultured in DMEM
containing 10% FBS. For insulin signaling, cells were serum starved for 16 h and
then treated with chelerythrine (2 µM) or protopine (2 µM) for 1 h. Following
which, cells were treated with 25 nM insulin for various times (0, 5, 10, 20 min) at
37 °C. Cells were washed with PBS and lysed in de-gassed RIPA lysis buffer (25
mM HEPES pH 7.5, 150 mM NaCl, 0.25% Deoxychloate, 10% Glycerol, 25 mM
NaF, 10 mM MgCl2, 1 mM EDTA, 1% Triton X-100, 0.5 mM PMSF, 10 mM
Benzamidine, cOmplete protease inhibitor cocktail (Roche)). Soluble proteins were
harvested by centrifugation at 13,000×g for 10 min at 4 °C and quantitated. Total
proteins in the cell lysates were separated by SDS-PAGE and tyrosyl phosphor-
ylation of the IR-β subunit and downstream AKT activation was monitored. To test
the effect of suppressing H2O2 levels on the function of the compounds, catalase
was ectopically expressed in cells for 24 h. Following which, the cells were treated
with the compounds as mentioned above. Phosphorylation of the AKT activation
loop at residue threonine 308 (T308) in response to insulin stimulation was
observed with the phospho-speciﬁc antibody. Catalase expression was detected in
the cell samples with a rabbit polyclonal antibody (Abcam, ab52477).
Effects of chelerythrine after PTP1B variant overexpression. Mammalian
expression plasmids used in this study were as follows: pCMV-FLAG and pCMV-
FLAG-PTP1B (wt and -mut2). Empty vector, FLAG-PTP1B-wt, or FLAG-PTP1B-
mut2 were transfected into 293T cells for 24 h, following which, cells were serum
starved for 8 h and then treated with chelerythrine (2 µM) for 1 h. Subsequently,
cells were treated with 10 nM insulin for various times (0, 10, 20 min) at 37 °C.
Cells were washed with PBS and lysed in de-gassed RIPA lysis buffer (25 mM
HEPES pH 7.5, 150 mM NaCl, 0.25% Deoxycholate, 10% Glycerol, 25 mM NaF, 10
mM MgCl2, 1 mM EDTA, 1% Triton X-100, 0.5 mM PMSF, 10 mM Benzamidine,
cOmplete protease inhibitor cocktail (Roche)). Soluble proteins were harvested by
centrifugation at 13,000×g for 10 min at 4 °C and quantitated. Total proteins in the
cell lysates were separated by SDS-PAGE and tyrosyl phosphorylation of the IR-β
subunit was analyzed by immunoblotting.
Leptin signaling in hepatic stellate cells. Human hepatic stellate cells (HSteCs;
ScienCell research laboratories, CA) were cultured according to manufacturer’s
instructions. Cells were seeded on poly-L-lysine coated dishes and maintained in
Stellate Cell Medium (SteCM, Cat. #5301). When cells reached 70% conﬂuency
they were split for various experiments. To study leptin signaling, HSCs were
incubated in serum-free DMEM for 24 h and then stimulated with varying con-
centration of leptin (0, 10, 25, 50, 100, and 200 ng ml−1) for 15 min. To study the
effect of chelerythrine and protopine, serum starved cells were incubated with the
compounds at varying concentrations (0–5 µM) for 1 h prior to leptin stimulation.
In some groups, cells were pre-incubated (60 min) with the NADPH oxidase
inhibitor apocynin (100 nM), before stimulation with leptin.
Measurement of intracellular ROS. Cells cultured in 24-well plates were washed
with PBS and changed to serum-free media 24 h before ROS measurement. Cells
were incubated with 2′,7′-dichloroﬂuorescin diacetate (DCFDA) (8 μM) for 20 min
at 37 °C. Cells were then rinsed twice with serum-free medium and stimulated with
varying concentrations of leptin. DCFDA ﬂuorescence was detected at excitation
and emission wavelengths of 488 and 520 nm, respectively, using a multi-well
ﬂuorescence scanner (Spectramax Gemini, molecular devices) continuously for 30
min.
Animal experiments. Animal experiments were performed according to protocols
approved by the Institutional Animal Use and Care Committee of Cold Spring
Harbor laboratory. Ten week-old male C57bl6/J mice fed chow diet or high fat diet
(D12492) were acclimatized for 10 days under standard conditions before
experiments. Mice were intraperitoneally (i.p.) injected once daily with vehicle, 3
mg kg−1 of chelerythrine or 3 mg kg−1 of protopine for 30 days. Mice were killed
after 6 h of fasting, and serum samples were collected to measure the metabolic
parameters and tissue samples were collected for studying changes in signaling. No
animals were excluded from the analysis.
Measurement of PTP1B oxidation in vivo. Mice fed normal or high fat diet were
administered saline, insulin (1 U kg−1) or leptin (1 mg kg−1) subcutaneously (s.c.).
Within 30 min after the treatment, animals were killed, tissues were dissected,
weighed, ﬂash-frozen in liquid nitrogen, and stored at −80 °C. For PTP oxidation,
liver tissue or hypothalamus were homogenized under anaerobic conditions in de-
gassed, ice-cold lysis buffer (25 mM HEPES pH 7.4, 100 mM NaCl, 10 mM N-
ethylmaleimide, 0.25% deoxychloate, 1% Triton X-100, 25 mM NaF, 10 mM
MgCl2, 1 mM EDTA, 10% glycerol, and cOmplete protease inhibitor cocktail) for 1
h at 4 °C. Lysates were clariﬁed by centrifugation at 16,000×g for 20 min and
diluted 100-fold using 25 mM HEPES, pH 7.4, 100 mM NaCl. Lysates were
quantitated and 1 mg of each lysate was incubated with scFv45 (0.1 mg ml−1) for
90 min. The protein complexes were precipitated with anti-HA-agarose beads and
washed three times; ﬁrst with lysis buffer followed by two more washes with wash
buffer (25 mM HEPES pH 7.4, 100 mM NaCl, 0.05% BSA, 0.05% Tween-20, and
protease inhibitors). Complexes were separated by SDS-PAGE and immunoblotted.
Metabolic measurements. Glucose in tail blood was measured using a glucometer
(One-Touch Basic; Lifescan, CA). For glucose tolerance tests (GTTs), mice were
fasted for 10 h and then injected with 20% D-glucose (2 mg g−1 body weight) and
the blood glucose was monitored immediately before and at 15, 30, 60, and 120 min
following the injection. For insulin tolerance tests (ITTs), 4 h fasted animals were
given insulin (0.75 mU g−1) and blood glucose was measured immediately before
and at 30, 60, and 120 min post-injection. Statistical analysis was performed using
ANOVA for both GTT and ITT.
Statistics and reproducibility. No statistical method was used to predetermine
sample sizes. Samples were not randomized. The investigators were not blinded to
allocation during experiments or outcome assessment. Sample sizes and statistical
tests for each experiment are denoted in the ﬁgure legends. Statistical analysis and
tests were chosen based on established protocols. Each immunoblot was performed
at least three times (biological replicates) for quantiﬁcation. Statistical analysis was
performed by using the two-tailed Student’s t-test (Figs. 6a, b and 7a, b), paired
two-way ANOVA (Figs. 8b and 9b–e). p-values can be found in corresponding
ﬁgure legends.
Data availability. Source data for ﬁgures are available from the corresponding
author upon request. Coordinates and structure factors for scFv45 have been
deposited in the Protein Data Bank under accession code 5VF6.
All uncropped blots are provided in Supplementary Fig. 18.
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